<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04190212</url>
  </required_header>
  <id_info>
    <org_study_id>20190687</org_study_id>
    <nct_id>NCT04190212</nct_id>
  </id_info>
  <brief_title>The Effect of High-Intensity Interval Training on Glucose Variability and Atrial Fibrillation Symptoms</brief_title>
  <acronym>Glucose-AF</acronym>
  <official_title>Examining the Role of High-intensity Interval Training on Glucose Variability and Symptomatology: A Novel Approach for Patients With Atrial Fibrillation and Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of atrial fibrillation (AF), the most common heart rhythm disorder, is
      increasing. The symptoms of AF include: unpleasant heartbeats; difficulty breathing;
      tiredness; dizziness; and, reduced exercise capacity. Patients with AF have lower quality of
      life, higher mental distress, and higher risk of heart disease and stroke when compared to
      the general population. Further, patients with non-permanent AF tend to experience more
      severe symptoms and substantial reductions in quality of life when compared to patients with
      permanent AF.

      Type 2 diabetes increases the risk of developing AF and accounts for about 20% of patients
      with non-permanent AF. High blood glucose concentrations and increased blood glucose
      fluctuations (large and frequent upward and downward blood glucose swings) are commonly seen
      in type 2 diabetes. Increased blood glucose fluctuations may worsen AF symptoms and quality
      of life in patients with AF.

      Exercise improves quality of life and mental health and reduces risk of developing heart
      disease and stroke. However, no clinical guidelines for managing AF include exercise.
      High-intensity interval training (HIIT), a form of exercise that alternates between intense
      bouts of exercise and less intense recovery periods, is a time-efficient approach to improve
      blood glucose fluctuations in type 2 diabetes. In healthy individuals and in patients with
      coronary artery disease, HIIT also improves quality of life and mental health. Currently, the
      effect of HIIT on blood glucose fluctuations, AF symptom severity and quality of life in
      patients with AF living with type 2 diabetes is unknown. Also, the links between blood
      glucose fluctuations and AF symptom severity and quality of life have not been investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a global epidemic of AF, the most common sustained cardiac arrhythmia, and type 2
      diabetes (T2D). Given an aging population and physically inactive lifestyles, the prevalence
      of AF and T2D is expected to increase. AF is a progressive disorder with three principal
      subtypes: paroxysmal AF (AF that self-terminates within &lt;7 days), persistent AF (AF that
      lasts &gt;7 days and is terminated by medications or procedures) and permanent AF (patient and
      treating physician agree not to pursue further intervention). AF-related symptoms are
      disabling and highly variable, including exercise intolerance, palpitations, breathlessness,
      fatigue, dizziness and mental distress. Patients with non-permanent AF experience more severe
      symptoms when compared to those with permanent AF, and suffer from substantial reductions in
      quality of life (QoL) and increased risk of major cerebrovascular events, cardiovascular
      events and mortality.

      T2D is a risk factor for developing AF and approximately 20% of non-permanent AF patients
      (i.e. paroxysmal and persistent AF) suffer from this condition. T2D is characterized by
      insulin resistance and insulin insufficiency leading to high blood glucose concentrations.
      Inadequate or poor glycemic control leads to increases in glycemic variability (GV, amplitude
      and frequency of blood glucose oscillations from either high to low or low to high). GV is
      considered to exacerbate AF symptoms severity by increasing: (1) inflammation; (2) oxidative
      stress; and, (3) autonomic nervous system dysfunction. Emerging evidence also highlights
      associations between GV and poor QoL and negative mood in patients with T2D.

      High-intensity interval training (HIIT), a form of exercise that involves periods of short,
      intense exercise bouts interspersed by less intense recovery periods, has emerged as a
      time-efficient and practical approach to improving GV. Importantly, only 10 HIIT sessions
      over 2 weeks have been shown to lower GV in patients with T2D. A systematic review (N=50
      studies) revealed that HIIT improves insulin resistance and blood glucose control (glycated
      hemoglobin A1C) when compared to controls (i.e. no exercise) in patients with metabolic
      syndrome or T2D. HIIT also increases QoL in patients with coronary artery disease (CAD)
      following 4 weeks of exercise training; reduces inflammatory markers (i.e. interleukin-6
      [IL-6] and C-reactive protein [CRP]30) in patients with CAD; attenuates markers of oxidative
      stress in healthy adults in 3 weeks; and improves cardiac autonomic nervous system function
      in healthy sedentary men in 2 weeks.

      The recent American Diabetes Association guidelines recommend HIIT as a strategy to control
      blood glucose in patients with T2D. However, neither national nor international clinical
      guidelines for managing AF include exercise. The absence of exercise from these guidelines in
      the face of increasing evidence of its physical and mental health benefits reflects a lost
      opportunity to provide AF patients with better treatment options, particularly those who
      suffer from concomitant T2D. The effects of HIIT on GV, AF symptom severity and QoL in
      non-permanent AF patients with T2D are unknown, and the associations between GV and AF
      symptom severity and QoL remain to be investigated. Examining the impact of HIIT on GV, AF
      symptom severity and QoL may provide a novel, feasible and time-efficient therapeutic option
      for non-permanent AF patients with T2D who are searching for better treatment options.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose variability</measure>
    <time_frame>From baseline to follow-up after 4-week intervention</time_frame>
    <description>Change in glucose variability as measured by the continuous glucose monitoring system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation symptom severity</measure>
    <time_frame>From baseline to follow-up after 4-week intervention</time_frame>
    <description>Changes in atrial fibrillation symptom severity as assessed by the University of Toronto Atrial Fibrillation Severity Scale (AFSS). The questions include: AF frequency; overall severity; duration of AF episodes; frequency of hospitalization, visits to emergency room and specialist; and overall well-being (Likert scale with 1 indicating &quot;worst possible life&quot; to 10 indicating &quot;best possible life&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation-related quality of life</measure>
    <time_frame>From baseline to follow-up after 4-week intervention</time_frame>
    <description>Change in the AF-related quality of life will be assessed by the Atrial Fibrillation Effect on Quality of Life (AFEQT) Questionnaire.The questionnaire includes Likert scale ranging from 1 to 7. The score will be transformed to a 0 to 100 scale where higher score represents better AF-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General quality of life</measure>
    <time_frame>From baseline to follow-up after 4-week intervention</time_frame>
    <description>Change in general quality of life will be assessed by the Short Form 36 Health Survey Questionnaire (SF-36). It yields an 8-scale profile of functional health and well-being scores, with higher scores indicating better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>From baseline to follow-up after 4-week intervention</time_frame>
    <description>Change in the sleep quality will be assessed by the 3-day sleep diary and Pittsburgh Sleep Quality index (PSQI). A global PSQI score ranges from 0 to 21 with higher scores indicating worse sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood biomarker concentrations</measure>
    <time_frame>From baseline to follow-up after 4-week intervention</time_frame>
    <description>Changes in the blood biomarker concentrations linked to glucose variability and AF symptom severity.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Link between glucose variability and atrial fibrillation symptom severity</measure>
    <time_frame>From baseline to follow-up after 4-week intervention</time_frame>
    <description>Correlation between glucose variability and atrial fibrillation symptom severity measured by the University of Toronto Atrial Fibrillation Severity Scale (AFSS)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>High-intensity interval training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will complete 12 supervised high-intensity interval exercise sessions (3 times weekly for 4 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will not participate in on-site supervised exercise sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>High-intensity interval training + standard care</intervention_name>
    <description>HIIT sessions will include: (1) warm-up for 2 minutes at 50% of peak power output (PPO); (2) 2 x 8-minute interval training blocks (total: 16 minutes) of 30-seconds at 80-100% of PPO interspersed with 30-seconds active recovery, 4 minutes of recovery will be permitted between the blocks; and, (3) 2 minute cool-down at 25% of PPO after the last 30-second exercise bout.</description>
    <arm_group_label>High-intensity interval training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-permanent atrial fibrillation

          -  diagnosed with type 2 diabetes

          -  non-smokers

          -  able to perform a symptom-limited cardiopulmonary exercise test (CPET)

          -  rate controlled with a resting ventricular rate of â‰¤110 beats per minute

        Exclusion Criteria:

          -  uncontrolled type 2 diabetes (A1C &gt;10 % or presence of type 2 diabetes-related
             complications

          -  on exogenous insulin

          -  unstable diagnosed angina

          -  diagnosed severe mitral or aortic stenosis

          -  diagnosed hypertrophic obstructive cardiomyopathy with significant obstruction

          -  presence of self-reported alcohol or substance abuse

          -  unable to provide written, informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer L Reed, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 29, 2019</study_first_submitted>
  <study_first_submitted_qc>December 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high-intensity interval training</keyword>
  <keyword>glycemic variability</keyword>
  <keyword>continuous glucose monitoring system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

